Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

First Posted Date
2021-05-04
Last Posted Date
2024-06-24
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
33
Registration Number
NCT04871607
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

First Posted Date
2021-05-03
Last Posted Date
2024-03-08
Lead Sponsor
AstraZeneca
Target Recruit Count
18
Registration Number
NCT04870112
Locations
🇨🇳

Research Site, Taipei City, Taiwan

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

First Posted Date
2021-04-06
Last Posted Date
2023-10-12
Lead Sponsor
GWT-TUD GmbH
Target Recruit Count
334
Registration Number
NCT04833114
Locations
🇩🇪

Universitätsklinikum Jena, Jena, Germany

🇩🇪

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

🇩🇪

DIAKO Ev.Diakonie-Krankenhaus gemeinnützige GmbH, Bremen, Germany

and more 61 locations

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

First Posted Date
2021-03-18
Last Posted Date
2024-11-12
Lead Sponsor
Nabil Adra
Target Recruit Count
64
Registration Number
NCT04804007
Locations
🇺🇸

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

First Posted Date
2021-03-17
Last Posted Date
2024-08-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
170
Registration Number
NCT04803201
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Memorial Hospital East, Shiloh, Illinois, United States

🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 74 locations

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

First Posted Date
2021-03-03
Last Posted Date
2024-10-08
Lead Sponsor
Gilead Sciences
Target Recruit Count
54
Registration Number
NCT04778410
Locations
🇺🇸

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 18 locations

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

First Posted Date
2021-03-01
Last Posted Date
2024-10-18
Lead Sponsor
AstraZeneca
Target Recruit Count
152
Registration Number
NCT04774380
Locations
🇹🇷

Research Site, Pamukkale, Turkey

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Phase 2
Recruiting
Conditions
Glioblastoma Multiforme
Interventions
Drug: Tamoxifen
Drug: Etoposide
First Posted Date
2021-02-21
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
60
Registration Number
NCT04765098
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Study of AZD2811 + Durvalumab in ES-SCLC

First Posted Date
2021-02-09
Last Posted Date
2022-12-15
Lead Sponsor
AstraZeneca
Target Recruit Count
31
Registration Number
NCT04745689
Locations
🇪🇸

Research Site, Valencia, Spain

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

First Posted Date
2021-02-05
Last Posted Date
2021-02-05
Lead Sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
Target Recruit Count
46
Registration Number
NCT04740021
Locations
🇨🇳

Affiliated Hospital Of Jiangnan University, Wuxi, Jiangsu, China

🇨🇳

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China

🇨🇳

Shandong Cancer Hospital, Jinan, Shandong, China

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy